3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
78
Precursor Cell Lymphoblastic Leukemia-Lymphoma
65
Myelodysplastic Syndromes
59
Leukemia, Lymphocytic, Chronic, B-Cell
56
Lymphoma, Non-Hodgkin
55
Multiple Myeloma
52
Hodgkin Disease
52
Leukemia
48
Lymphoma, Mantle-Cell
43
Lymphoma
39
Lymphoma, Follicular
38
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
38
Myeloproliferative Disorders
36
Lymphoma, B-Cell, Marginal Zone
36
Lymphoma, Large B-Cell, Diffuse
35
Burkitt Lymphoma
34
Leukemia, Myelomonocytic, Chronic
30
Congenital Abnormalities
30
Lymphoma, Large-Cell, Immunoblastic
27
Waldenstrom Macroglobulinemia
26
Leukemia, Myeloid, Accelerated Phase
25
Leukemia, Myeloid, Chronic-Phase
23
Hematologic Neoplasms
22
Blast Crisis
22
Primary Myelofibrosis
21
Anemia, Refractory, with Excess of Blasts
21
Dendritic Cell Sarcoma, Interdigitating
20
Lymphoma, T-Cell, Cutaneous
18
Lymphoma, Large-Cell, Anaplastic
18
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
17
Interventions
blinatumomab
6
Cyclophosphamide
5
Rituximab
4
Tacrolimus
3
ponatinib
2
fludarabine
2
denileukin diftitox
2
Vorinostat
2
Vincristine
2
Prednisone
2
Peripheral Blood Stem Cell Transplantation
2
Methotrexate
2
Everolimus
2
Etoposide
2
Doxorubicin
2
Darbepoetin alfa
2
Cytarabine
2
Busulfan
2
Brentuximab Vedotin
2
Antilymphocyte Serum
2
Alemtuzumab
2
tetulomab tetraxetan lu-177
1
ruxolitinib
1
pembrolizumab
1
pegaspargase
1
ibrutinib
1
ibritumomab tiuxetan
1
fludarabine phosphate
1
ferrous sulfate
1
ferric gluconate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Lymphoproliferative Disorders
×
Whole-Body Irradiation
×
Clear all
NCT00368355
2020-01-21
MOHEL
Baylor College of Medicine
Phase 2
Completed
46 enrolled
12 charts